Elicio Therapeutics Inc (ELTX)

Currency in USD
2.80
-0.11(-3.78%)
Closed·
2.72-0.08(-2.86%)
·
Earnings results expected in 4 days
ELTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.722.96
52 wk Range
2.6616.00
Key Statistics
Prev. Close
2.8
Open
2.96
Day's Range
2.72-2.96
52 wk Range
2.66-16
Volume
406.91K
Average Volume (3m)
1.69M
1-Year Change
-71.9439%
Book Value / Share
-0.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.00
Upside
+614.29%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Elicio Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.00
(+614.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy23.00+721.43%-MaintainJun 22, 2026
Ladenburg Thalmann
Buy12.00+328.57%-New CoverageJun 18, 2026
Jones Trading
Hold---DowngradeJun 15, 2026
Rodman & Renshaw
Buy17.50+525.00%17.00MaintainJun 15, 2026
H.C. Wainwright
Buy23.00+721.43%-MaintainJun 15, 2026

Earnings

Latest Release
May 11, 2026
EPS / Forecast
-0.65 / -0.61
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ELTX Income Statement

Compare ELTX to Peers and Sector

Metrics to compare
ELTX
Peers
Sector
Relationship
P/E Ratio
−1.6x−2.9x−0.4x
PEG Ratio
−0.04−0.030.00
Price/Book
−45.7x6.3x2.6x
Price / LTM Sales
-10.9x3.0x
Upside (Analyst Target)
-174.7%56.0%
Fair Value Upside
Unlock−22.9%9.1%Unlock

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.44M6.15%4.04M
Other Institutional Investors
3.64M15.54%10.20M
Public Companies & Retail Investors
18.37M78.31%51.42M
Total
23.45M100.00%65.67M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Moti Investments LLC6.01%1,408,8923,945
Knoll Capital Management5.17%1,211,9573,393

People Also Watch

2.65
SLBT
-1.49%
1.23
CAST
-6.82%
1.74
RGNT
-3.33%
0.95
GLXG
-3.06%
2.02
EHGO
-3.81%

FAQ

What Is the Elicio Therapeutics (ELTX) Stock Price Today?

The Elicio Therapeutics stock price today is 2.80 USD.

What Stock Exchange Does Elicio Therapeutics Trade On?

Elicio Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Elicio Therapeutics?

The stock symbol for Elicio Therapeutics is "ELTX."

What Is the Elicio Therapeutics Market Cap?

As of today, Elicio Therapeutics market cap is 65.67M USD.

What Is Elicio Therapeutics's Earnings Per Share (TTM)?

The Elicio Therapeutics EPS (TTM) is -2.42.

When Is the Next Elicio Therapeutics Earnings Date?

Elicio Therapeutics will release its next earnings report on Aug 07, 2026.

From a Technical Analysis Perspective, Is ELTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Elicio Therapeutics Stock Split?

Elicio Therapeutics has split 0 times.

How Many Employees Does Elicio Therapeutics Have?

Elicio Therapeutics has 33 employees.

What is the current trading status of Elicio Therapeutics (ELTX)?

As of Aug 03, 2026, Elicio Therapeutics (ELTX) is trading at a price of 2.80 USD, with a previous close of 2.80 USD. The stock has fluctuated within a day range of 2.72 USD to 2.96 USD, while its 52-week range spans from 2.66 USD to 16.00 USD.

What Is Elicio Therapeutics (ELTX) Price Target According to Analysts?

The average 12-month price target for Elicio Therapeutics is 20.00 USD, with a high estimate of 27 USD and a low estimate of 10 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +614.29% Upside potential.

What Is the ELTX Premarket Price?

ELTX's last pre-market stock price is 2.72 USD. The pre-market share volume is 1,360.00, and the stock has decreased by -0.08, or -2.86%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.